A phase I expansion study to evaluate the efficacy and safety of Altiratinib in patients with actionable MET and TRK genomic alterations.

Trial Profile

A phase I expansion study to evaluate the efficacy and safety of Altiratinib in patients with actionable MET and TRK genomic alterations.

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Altiratinib (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jan 2016 New trial record
    • 05 Jan 2016 According to Deciphera Pharmaceuticals media release, the phase I expansion trials of altiratinib in patients with actionable MET and TRK genomic alterations are expected to start early in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top